GHRP-2 vs GHRP-6

Overview

GHRP-2 and GHRP-6 are both synthetic growth hormone releasing peptides that stimulate GH secretion through the ghrelin receptor (GHS-R1a). Developed in the 1980s-1990s as research tools, neither has received regulatory approval for clinical use. They remain research chemicals with different profiles of action.

This comparison is relevant because both peptides are commonly encountered in research contexts and have distinct characteristics despite their similar mechanisms.

Key Facts

Aspect	GHRP-2	GHRP-6
Class	Growth Hormone Releasing Peptide	Growth Hormone Releasing Peptide
Structure	Hexapeptide	Hexapeptide
Target	GHS-R1a (Ghrelin receptor)	GHS-R1a (Ghrelin receptor)
FDA Status	Not approved	Not approved
WADA Status	Prohibited	Prohibited

Structure Comparison

Aspect	GHRP-2	GHRP-6
Sequence	D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH₂	His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Amino Acids	6	6
Key Difference	β-naphthyl alanine	Histidine N-terminus
Molecular Weight	~818 Da	~873 Da

Mechanism Comparison

Aspect	GHRP-2	GHRP-6
Primary Target	GHS-R1a	GHS-R1a
GH Release	Strong	Moderate-Strong
Ghrelin Mimetic	Yes (partial)	Yes (stronger)
Hunger Effect	Mild	Pronounced

GH Release Characteristics

Both peptides stimulate GH release through:

1. Direct pituitary action via GHS-R1a
2. Hypothalamic GHRH release
3. Suppression of somatostatin

Factor	GHRP-2	GHRP-6
Relative GH Potency	Higher	Lower
Desensitization	Less likely	More likely with frequent dosing
Pulse Pattern	More consistent	Variable

Research Findings

GH Release Studies

Parameter	GHRP-2	GHRP-6
Peak GH Increase	3-6x baseline	2-4x baseline
Time to Peak	15-30 minutes	15-30 minutes
Duration	2-3 hours	2-3 hours

Note: These are approximate values from research studies; individual responses vary.

Additional Effects (Preclinical)

Effect	GHRP-2	GHRP-6
Cortisol	Modest increase	Modest increase
Prolactin	Mild increase	Mild increase
ACTH	Some effect	Some effect
IGF-1	Increased with repeated use	Increased with repeated use

Side Effect Comparison

Appetite Effects

Aspect	GHRP-2	GHRP-6
Hunger Increase	Mild to moderate	Significant
Mechanism	Partial ghrelin mimetic	Strong ghrelin mimetic
Onset	Variable	Rapid (within minutes)

Other Effects

Side Effect	GHRP-2	GHRP-6
Water Retention	Possible	Possible
Cortisol Elevation	Transient	Transient
Prolactin Elevation	Possible	Possible
Injection Site	Possible irritation	Possible irritation

Safety Concerns (Both)

• Long-term safety unknown
• Theoretical tumor promotion (GH/IGF-1 axis)
• Unknown interactions
• Quality/purity issues (unregulated)

Administration (Research Context)

Aspect	GHRP-2	GHRP-6
Route	Subcutaneous/IV (research)	Subcutaneous/IV (research)
Combination	Often with GHRH analog	Often with GHRH analog

Synergy with GHRH Analogs

Both GHRPs are often studied in combination with GHRH analogs (like CJC-1295 or Sermorelin) because:

• Different mechanisms of action
• Potentially synergistic GH release
• More physiological pulse pattern

Evidence Quality

Factor	GHRP-2	GHRP-6
Human Studies	Limited	Limited
Controlled Trials	Few	Few
Long-term Data	None	None
Regulatory Review	Not submitted	Not submitted

Research Context

Aspect	GHRP-2	GHRP-6
Academic Research	Used as tool	Used as tool
Clinical Development	None active	None active
Publication Quality	Variable	Variable

Comparison with Other Secretagogues

Factor	GHRP-2	GHRP-6	Ipamorelin	MK-677
GH Potency	High	Moderate	Moderate	Moderate
Selectivity	Moderate	Lower	Higher	Moderate
Hunger Effect	Mild	Strong	Minimal	Moderate
Cortisol Effect	Some	Some	Minimal	Minimal
Route	Injectable	Injectable	Injectable	Oral

Regulatory and Legal Status

Aspect	GHRP-2	GHRP-6
FDA Status	Not approved	Not approved
Clinical Use	Not indicated	Not indicated
WADA	Prohibited (S2)	Prohibited (S2)
DEA Schedule	Not scheduled	Not scheduled
Legal Status	Research chemical	Research chemical

Quality Concerns

Both peptides, when obtained outside of regulated research:

• No quality assurance
• Variable purity
• Potential contaminants
• Mislabeling risk
• Degradation concerns

Summary

Factor	GHRP-2	GHRP-6
GH Release	Higher	Lower
Selectivity	Moderate	Lower
Hunger Effect	Mild	Strong
Evidence Level	Moderate	Moderate
Approval Status	Not approved	Not approved

Key Takeaways

1. Both are unapproved: Neither GHRP-2 nor GHRP-6 is approved for clinical use
2. GHRP-2 is more potent: Generally produces stronger GH release
3. GHRP-6 increases hunger: More pronounced appetite stimulation
4. Both lack long-term data: Safety profiles are not established
5. Prohibited in sport: Both are on the WADA banned list
6. Research tools only: Primarily used in academic/research settings
7. Quality concerns: Products from unregulated sources have unknown purity

---

This comparison is for educational purposes only. Neither peptide is approved by regulatory agencies. Products sold as research chemicals have uncertain quality and safety.